🚀 Gate Square Creator Certification Incentive Program Is Live! 
Join Gate Square and share over $10,000 in monthly creator rewards! 
Whether you’re an active Gate Square creator or an established voice on another platform, consistent quality content can earn you token rewards, exclusive Gate merch, and massive traffic exposure! 
✅ Eligibility: 
You can apply if you meet any of the following: 
1️⃣ Verified creator on another platform 
2️⃣ At least 1,000 followers on a single platform (no combined total) 
3️⃣ Gate Square certified creator meeting follower and engagement criteria 
Click to apply now 👉 
Goldman Sachs: WuXi AppTec's last quarter profit exceeded expectations, follow the momentum of new orders and clinical CRO business.
Jin10 data reported on October 28, Goldman Sachs published a research report indicating that the market is expected to respond positively to WuXi AppTec (02359.HK) strong performance and new order momentum, although the slowdown in the growth of TIDES (oligonucleotide and peptide) order backlog may spark some controversy. WuXi AppTec's third-quarter revenue reached 12.1 billion yuan, a year-on-year rise of 15.3%, or a year-on-year rise of 19.7% based on continuing operations. Notably, the TIDES business grew 91% year-on-year, accounting for 23% of current total revenue. Goldman Sachs set a 12-month target price of HKD 109.6 for WuXi AppTec's Hong Kong stock, based on a 12-month forward price-to-earnings ratio of 18 times. WuXi AppTec (603259.SH) A-shares have a target price of 105.6 yuan.